Literature DB >> 2243896

Effects of serotonin antagonists on m-chlorophenylpiperazine-mediated responses in normal subjects.

R S Kahn1, O Kalus, S Wetzler, W Cahn, G M Asnis, H M van Praag.   

Abstract

The serotonin (5HT) agonist, m-chlorophenylpiperazine (MCPP), has been used as a challenge agent to assess central 5HT receptor sensitivity in normal subjects and patients with panic disorder, obsessive-compulsive disorder, and major depression. Adrenocorticotropin, cortisol, and prolactin responses to MCPP were among the variables measured. MCPP's usefulness as a probe of 5HT receptors, however, hinges on its 5HT selectivity. To address MCPP's selectivity for 5HT, this study tested whether two different 5HT antagonists, methysergide (4 mg p.o.) and metergoline (4 mg p.o.), could block the hormonal and behavioral effects of MCPP (0.5 mg/kg p.o.) in 10 normal male subjects in comparison to placebo. Both 5HT antagonists abolished the prolactin release to MCPP. Metergoline, the antagonist with the more potent 5HT binding affinity, significantly blocked MCPP's effect on cortisol release as compared to placebo, and methysergide showed a nonsignificant trend to that effect. MCPP alone did not have a significant effect on behavioral variables, perhaps explaining why neither 5HT antagonist affected these measures. The findings from this study suggest that both MCPP-induced prolactin release and cortisol release are indeed 5HT-mediated effects.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2243896     DOI: 10.1016/0165-1781(90)90073-e

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  8 in total

1.  Daily administration of m-chlorophenylpiperazine to healthy human volunteers rapidly attenuates many of its behavioral, hormonal, cardiovascular and temperature effects.

Authors:  J Benjamin; B D Greenberg; D L Murphy
Journal:  Psychopharmacology (Berl)       Date:  1996-09       Impact factor: 4.530

2.  5-HT2a/2c receptor blockade by amesergide fully attenuates prolactin response to d-fenfluramine challenge in physically healthy human subjects.

Authors:  E F Coccaro; R J Kavoussi; M Oakes; T B Cooper; R Hauger
Journal:  Psychopharmacology (Berl)       Date:  1996-07       Impact factor: 4.530

3.  A dose-response study of intravenous m-chlorophenylpiperazine in normal subjects.

Authors:  O Kalus; S Wetzler; R S Kahn; G M Asnis; H M van Praag
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 4.  Eating disorder and obsessive-compulsive disorder: neurochemical and phenomenological commonalities.

Authors:  J L Jarry; F J Vaccarino
Journal:  J Psychiatry Neurosci       Date:  1996-01       Impact factor: 6.186

Review 5.  5-Hydroxytryptamine (5-HT) and the initiation of migraine: new perspectives.

Authors:  J R Fozard; H O Kalkman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-09       Impact factor: 3.000

6.  Haloperidol and clozapine treatment and their effect on M-chlorophenylpiperazine-mediated responses in schizophrenia: implications for the mechanism of action of clozapine.

Authors:  R S Kahn; L Siever; M Davidson; C Greenwald; C Moore
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

7.  The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of m-chlorophenylpiperazine.

Authors:  D Fiorella; R A Rabin; J C Winter
Journal:  Psychopharmacology (Berl)       Date:  1995-05       Impact factor: 4.530

8.  Evidence for 5-hydroxytryptamine1A receptor involvement in the control of prolactin secretion in man.

Authors:  E Palazidou; J Stephenson; J Butler; P Coskeran; S Chambers; A M McGregor
Journal:  Psychopharmacology (Berl)       Date:  1995-06       Impact factor: 4.530

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.